article thumbnail

Parallel import of medicinal products: regulatory update

European Pharmaceutical Review

This is due to the regulatory requirements imposed on parallel imported medicinal products in various Member States, the fulfilment of which often requires repackaging. Repackaging a medicinal product… means that the trademark is reapplied by an entity other than the trademark proprietor.”

article thumbnail

What happened to all the antibiotics?

pharmaphorum

These include allowing the exceptional supply of certain medicines that may not be authorised in a particular Member State or granting full or partial exemptions to certain labelling and packaging requirements to address severe problems in respect of the availability of some medicines.”

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

Certain groups of individuals may then not trust that the medicines have been produced with them in mind and may be highly sceptical of the resulting evidence base and prescribing label of medicines. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.

Packaging 128